Cite
HARVARD Citation
Jiang, T. et al. (2019). EGFR‐TKIs plus local therapy demonstrated survival benefit than EGFR‐TKIs alone in EGFR‐mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases. International journal of cancer. 144 (10), pp. 2605-2612. [Online].